Since then, Theresa has been undetectable for over a year, and she continues treatment with Keytruda, with little to no side effects. Her family remains hopeful and grateful that everything is going well for Theresa and they pray for her continued strength.

Keytruda works by binding to PD-1 and therefore blocking the cancer cells from using their own protein to slot into the same spot and switch off the immune cells. So with Keytruda, the T-cells do their job and effectively attack the cancer. Keytruda is also known as an anti PD-1 immunotherapy.

Keytruda given every 3 weeks reduced the risk of cancer spreading, growing, or getting worse by 42% compared to Yervoy. Half (50%) of the patients who received Keytruda every 3 weeks were alive at 4.1 months, compared to 2.8 months for patients receiving Yervoy.

KEYTRUDA is a prescription medicine used to treat a kind of cancer called triple-negative breast cancer (TNBC). KEYTRUDA may be used with chemotherapy medicines when your breast cancer has returned and cannot be removed by surgery or has spread, and tests positive for “PD-L1.” PD-L1 = programmed death ligand 1.

In one clinical study of people with urothelial cancer that couldn't be treated by certain chemotherapy drugs: 20% of people who took Keytruda had their cancer partially go away. 10% of people who took Keytruda had their cancer completely go away.

KEYTRUDA blocks the PD-1 pathway to help prevent cancer cells from hiding. KEYTRUDA is a type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding. KEYTRUDA helps the immune system do what it was meant to do: detect and fight cancer cells.

Some patients can stay on KEYTRUDA for up to a year or two. Your doctor will decide how long you will be on treatment. Always talk to your doctor about what to expect while taking KEYTRUDA.

KEYTRUDA blocks the PD-1 pathway to help prevent cancer cells from hiding. KEYTRUDA is a type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding. KEYTRUDA helps the immune system do what it was meant to do: detect and fight cancer cells.

Some patients can stay on KEYTRUDA for up to a year or two. Your doctor will decide how long you will be on treatment. Always talk to your doctor about what to expect while taking KEYTRUDA.

KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time.

Keytruda given every 3 weeks reduced the risk of cancer spreading, growing, or getting worse by 42% compared to Yervoy. Half (50%) of the patients who received Keytruda every 3 weeks were alive at 4.1 months, compared to 2.8 months for patients receiving Yervoy.

Pembrolizumab (brand name: Keytruda) from Merck was first approved in September 2014 and since that time over 19 cancer uses have been approved by the FDA. It treats cancers ranging from advanced skin cancer, to bladder cancer to lung cancer.